Objective: This study aims to construct a prognostic risk assessment model (PRAM) for non-small cell lung cancer (NSCLC) using radiomics and miRNA-10b expression. Patients and Methods: This study included 30 participants who underwent surgery or chemotherapy, and patient data were collected and analyzed. miRNA-10b mRNA in peripheral blood mononuclear cells was detected using RT-PCR. Tumor area was assessed by CT scan before and after treatment. The model was validated using internal and external data (using fivefold cross-validation) to ensure stability. Results: Posttreatment miRNA-10b mRNA levels were significantly downregulated compared with pretreatment levels. The integration of radiomics and miRNA-10b expression provided a robust prognostic tool, effectively distinguishing between favorable and poor outcomes. Conclusions: The combination of radiomics and miRNA-10b expression levels can be used to establish a reliable PRAM for NSCLC, enhancing prognostic accuracy and aiding in personalized treatment strategies. This dual-modality approach represents a significant advancement in the prognostic evaluation of NSCLC.
Yang et al. (Tue,) studied this question.